Semagludtide

DRUG2 trials

Sponsors

Novo Nordisk A/S, Lumos Pharma

Conditions

Early Alzheimer's DiseaseObesity & Overweight

Phase 2

Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

Not yet recruitingNCT07754045

Lumos PharmaObesity & Overweight

Start: 2027-02-15End: 2028-02-15Target: 202Updated: 2026-08-10

Phase 3

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

CompletedNCT04777396

Novo Nordisk A/SEarly Alzheimer's Disease

Start: 2021-05-18End: 2026-01-30Updated: 2026-07-07

Related Papers

Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.

2026-01-10

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease

Alzheimer s Research & Therapy2025-01-0882 citations

Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD

Alzheimer s & Dementia2024-12-01

Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease

Alzheimer s & Dementia2024-12-01

Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design

Alzheimer s & Dementia2024-12-01

Effect of an 18-month meditation training on cardiovascular risk in older adults: a secondary analysis of the Age-Well randomized controlled trial.

2024-11-16

Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

Journal of Alzheimer s Disease2024-10-188 citations

Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method.

2024-09-0510 citations

Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.

2024-04-0218 citations

Preliminary baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer’s disease

Arquivos de Neuro-Psiquiatria2024-01-01

evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease

Alzheimer s & Dementia2022-12-0123 citations

Investigating changes in fluid biomarkers in early Alzheimer’s disease: design of plasma biomarker analyses and a cerebrospinal fluid sub‐study in the evoke and evoke+ trials of semaglutide versus placebo

Alzheimer s & Dementia2022-12-011 citations